Arkolith/Insider Trading/SPRO/Form 4

Shukla Sath

CEO and President, DirectorSpero Therapeutics, Inc. (SPRO) · full profile →Form 4 · filed Feb 5, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$108K
Net Open-Market Flow
-$108K
Transactions
3
3 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 5, 2024Sell(S)45K$1.45$65K1.2M
Feb 2, 2024Sell(S)31K$1.37$42K1.2M
Feb 1, 2024Grant(A)680K—$01.3M

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-011487) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML